MC said, "I hear a lot of questions on where's UAE. There was originally at the end of the table with one partner for just one country with the CEO switch. We are looking for strategic partners around sections of the world so for example signing 20 partners off to run 20 different countries in the Middle East would create 20 different confusing points of contact for our company versus finding one strategic partner for making up the Middle East plus India."
There are four possible partners, each covers both ME (UAE, Saudi Arabia, Oman), India: Biocon in India, Wockhardt in India, Julphar in the United Arab Emirates, Cipla in India.
The later also covers S Africa.
www.julphar.net/company-profileJulphar Gulf Pharmaceutical Industries is the largest generic pharmaceutical manufacturer in Middle East and North Africa and distributes medicines to over 40 countries. Established in 1980 in the United Arab Emirates under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi, Julphar's first stand-alone facility produced only five products. Over three decades later, we operate sixteen internationally certified manufacturing facilities globally, produce over a million boxes of medicines daily and hold 4,074 product registration certificates.
Thirteen of our facilities are based in the UAE and cover production areas including tablets, syrups and suspensions. Julphar has also launched manufacturing facilities in Ethiopia, Bangladesh and Saudi Arabia as part of its ongoing international expansion strategy.
In 2012 Julphar launched a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility – Julphar Diabetes – entirely dedicated to producing raw material needed for insulin formulation. Julphar Diabetes has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA), equivalent to 40 million vials of insulin per year. This positions Julphar among the largest manufacturers of insulin in the world, and the only one of its kind in the Middle East.
Julphar maintains a diverse product portfolio which targets major therapeutic segments. It includes the following categories: Wound, Anemia and Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care.
As part of its on-going responsibility, Julphar partners with local and global companies to make a positive impact across all healthcare sectors by funding scholarships for educational facilities and by providing sponsorship of various health campaigns across MENA.
Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.45 billion in the year ending 2016, demonstrating a significant growth based on last year's results. Emerging markets remain a key priority for sustainable growth, as Julphar’s Middle Eastern roots allow us to reach difficult markets in a timely manner.
With 83 registered products sold in over 40 countries, Julphar is a stellar example of one of the UAE’s local businesses making an impact on the global stage.
Julphar is Current Good Manufacturing Practice (cGMP) compliant and has gained ISO9001 and ISO 14001 accreditations, as well as the EU Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certifications. We work closely with regulatory bodies, such as the UAE Ministry of Health (MOH) and the US Food and Drug Administration (FDA) to ensure all our practices are aligned with the international requirements.
Julphar in essence is Sustaining Health across the globe.
www.medscape.com/viewarticle/855774Mr Knox and colleagues analyzed market data for 121 countries, representing 96% of the world's population with diabetes. They identified a total of 42 insulin manufacturers selling their products in various parts of the world. The "Big 3" — Denmark-based Novo Nordisk, United States–based Eli Lilly, and France-based Sanofi — accounted for a total 93% of the insulin market by revenue and 92% by insulin production.
Of the other 39, another four companies — Bioton in Poland, Biocon in India, Wockhardt in India, and
Julphar in the United Arab Emirates — currently have their insulins registered and/or sold in 10 to 30 countries each and could potentially expand to help ease access barriers elsewhere, Mr Knox said.
Read more:
mnkd.proboards.com/user/1882/recent#ixzz4xp6FtIP2www.julpharbd.com/content.php?cid=9&type=abJulphar Bangladesh Ltd., a subsidiary of Julphar, UAE, started its journey on July 31, 2009. The visionary leader, His Highness the ruler of Ras Al Khaimah (RAK), Sheikh Saud Bin Saqr Al Qusimi the architect of the global conglomerate RAK Group, initiated the journey of Julphar Bangladesh Ltd.
The state of the art manufacturing facilities with an area of 228,705 sq ft is located 42 kilometers north of Dhaka under Sreepur Upazilla of Gazipur District. The facilities have the strength of general manufacturing unit, dedicated Cephalosporin unit, advanced three layer floors, prototype R & D laboratories, Effluent Treatment Plant (ETP) & advanced water treatment system with recycling facilities. Presently Julphar Bangladesh Ltd. has more than 100 products including Antibiotics/ Antimicrobials, Anti-ulcerants, Anti-inflammatory, Anti-hypertensive, Oral Anti-diabetics, Dermatological and Nutritional supplements.
With a vision of being a truly global company, Julphar Bangladesh Ltd. started its operation with strict compliance to WHO GMP, USFDA & TGA guideline, sourcing API (Active Pharmaceuticals ingredients) mainly from certified sources and caring to the environment fully. Now Julphar Bangladesh Ltd. is the only company in Bangladesh has achieved the prestigious GPM compliance certification from The Ministry of Health, UAE.
"These purposes may include:
raising capital; providing equity incentives to employees, officers and directors;
establishing strategic relationships with other companies [partnership with equity stake in Mnkd] expanding business or product lines through the acquisition of other businesses or products; and other purposes.
The additional shares of common stock that would become available for issuance if the proposal is adopted could also be used by the Company to
oppose a hostile takeover attempt or to delay or prevent changes in control or management of the Company. For example, without further stockholder
approval, the Board could strategically sell shares of common stock in a private transaction to purchasers who would oppose a takeover or favor the current Board. Although this proposal to increase the authorized common stock has been prompted by business and financial considerations and not by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts directed at the Company),"
[aka
Poison Pill]
Right on cue, the additional 140M shares will address Maxim's concerns.
"The hope had been with roughly $120 million, the company would be able to show enough share gains to project a robust launch trajectory, setting the stage for additional capital, but at a higher valuation.
Afrezza is both a promotionally sensitive and an education-driven product. Changing user awareness and habits will take time. Our revenue forecast assuming MannKind has the needed capital to invest in marketing suggests break-even is possible by 2020. We assume MannKind will need to raise at least an additional $150 million-$300 million."
www.biocon.com/biocon_aboutus.aspAs India's largest domestic branded biologics company, we have taken key products like INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody, from discovery to commercialization.
Generic Insulins and Biosimilars Pipeline
